Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | PDE2A | O00408 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | POLQ | O75417 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275926 | 0.86 | KIF11 (0.47) | IDO1KIF11 | |
| SCHEMBL13437709 | 0.85 | IDO1 (0.53) | IDO1DAOPDE2AGAACES2 | |
| SCHEMBL2316538 | 0.84 | MEN1 (0.41) | IDO1DAOPDE2ACES2MEN1 | |
| SCHEMBL585296 | 0.82 | IDO1 (0.54) | IDO1DAOSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL22573228 | 0.81 | ALDH1A1 (0.47) | IDO1SLC6A4SLC6A2SLC6A3GAA | |
| SCHEMBL22265163 | 0.81 | DAO (0.47) | IDO1DAOPDE2ACES2MEN1 | |
| SCHEMBL6193600 | 0.81 | DAO (0.47) | IDO1DAOCES2POLQ | |
| SCHEMBL1428445 | 0.81 | EPHX2 (0.37) | IDO1DAOSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6864791 | 0.79 | CES2 (0.47) | IDO1DAOCES2POLQKIF11 | |
| SCHEMBL28743564 | 0.79 | IDO1 (0.50) | IDO1DAOSLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4097097-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021154796-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-3774782-A2 | ATF6 INHIBITORS AND USES THEREOF | Black Belt TX Ltd (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3294297-A1 | PYRIMIDINONE AMIDE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-3291817-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-3285581-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016186888-A1 | PYRIMIDINONE AMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016179059-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016154081-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
| EP-2629851-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012054716-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV. (BE) | 2012-04-26 | — | — | WO | disclosed |
| EP-2300423-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-30 | — | — | EP | disclosed |
| US-7696238-B2 | Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics | GRUENENTHAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| WO-2009156072-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-30 | — | — | WO | disclosed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-4267359-A | Novel carboxylic acid esters | ZOECON CORPORATION (US) | 1981-05-12 | — | — | US | disclosed |
| US-4204071-A | 4-Aryl-3-butenoic acids and lower alkyl esters | ZOECON CORPORATION (US) | 1980-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | KCNQ1, KCNQ2, KCNQ3 | IDO1 1680/4885DAO 1586/4885SLC6A4 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.